Literature DB >> 25620824

A Multiresolution Hazard Model for Multicenter Survival Studies: Application to Tamoxifen Treatment in Early Stage Breast Cancer.

Peter Bouman1, Xiao-Li Meng2, James Dignam3, Vanja Dukić3.   

Abstract

In multicenter studies, one often needs to make inference about a population survival curve based on multiple, possibly heterogeneous survival data from individual centers. We investigate a flexible Bayesian method for estimating a population survival curve based on a semiparametric multiresolution hazard model that can incorporate covariates and account for center heterogeneity. The method yields a smooth estimate of the survival curve for "multiple resolutions" or time scales of interest. The Bayesian model used has the capability to accommodate general forms of censoring and a priori smoothness assumptions. We develop a model checking and diagnostic technique based on the posterior predictive distribution and use it to identify departures from the model assumptions. The hazard estimator is used to analyze data from 110 centers that participated in a multicenter randomized clinical trial to evaluate tamoxifen in the treatment of early stage breast cancer. Of particular interest are the estimates of center heterogeneity in the baseline hazard curves and in the treatment effects, after adjustment for a few key clinical covariates. Our analysis suggests that the treatment effect estimates are rather robust, even for a collection of small trial centers, despite variations in center characteristics.

Entities:  

Keywords:  Bayesian survival analysis; Breast cancer; Clinical trials; Hazard estimation; Kaplan–Meier estimator; Meta-analysis; Multicenter study; Multiresolution models; Posterior predictive check; Tamoxifen

Year:  2007        PMID: 25620824      PMCID: PMC4302949          DOI: 10.1198/016214506000000951

Source DB:  PubMed          Journal:  J Am Stat Assoc        ISSN: 0162-1459            Impact factor:   5.033


  13 in total

1.  Modelling clustered survival data from multicentre clinical trials.

Authors:  David V Glidden; Eric Vittinghoff
Journal:  Stat Med       Date:  2004-02-15       Impact factor: 2.373

2.  Stochastic relaxation, gibbs distributions, and the bayesian restoration of images.

Authors:  S Geman; D Geman
Journal:  IEEE Trans Pattern Anal Mach Intell       Date:  1984-06       Impact factor: 6.226

3.  An assessment of methods to combine published survival curves.

Authors:  C C Earle; B Pham; G A Wells
Journal:  Med Decis Making       Date:  2000 Jan-Mar       Impact factor: 2.583

4.  Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints.

Authors:  M K Parmar; V Torri; L Stewart
Journal:  Stat Med       Date:  1998-12-30       Impact factor: 2.373

5.  A Bayesian analysis of institutional effects in a multicenter cancer clinical trial.

Authors:  R J Gray
Journal:  Biometrics       Date:  1994-03       Impact factor: 2.571

6.  Meta-analysis of failure-time data with adjustment for covariates.

Authors:  M G Hunink; J B Wong
Journal:  Med Decis Making       Date:  1994 Jan-Mar       Impact factor: 2.583

7.  Properties of proportional-hazards score tests under misspecified regression models.

Authors:  S W Lagakos; D A Schoenfeld
Journal:  Biometrics       Date:  1984-12       Impact factor: 2.571

8.  S-phase fraction combined with other patient and tumor characteristics for the prognosis of node-negative, estrogen-receptor-positive breast cancer.

Authors:  J Bryant; B Fisher; N Gündüz; J P Costantino; B Emir
Journal:  Breast Cancer Res Treat       Date:  1998       Impact factor: 4.872

9.  Treatment of lymph-node-negative, oestrogen-receptor-positive breast cancer: long-term findings from National Surgical Adjuvant Breast and Bowel Project randomised clinical trials.

Authors:  Bernard Fisher; Jong-Hyeon Jeong; John Bryant; Stewart Anderson; James Dignam; Edwin R Fisher; Norman Wolmark
Journal:  Lancet       Date:  2004 Sep 4-10       Impact factor: 79.321

10.  A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors.

Authors:  B Fisher; J Costantino; C Redmond; R Poisson; D Bowman; J Couture; N V Dimitrov; N Wolmark; D L Wickerham; E R Fisher
Journal:  N Engl J Med       Date:  1989-02-23       Impact factor: 91.245

View more
  3 in total

1.  Survival Analysis with Electronic Health Record Data: Experiments with Chronic Kidney Disease.

Authors:  Yolanda Hagar; David Albers; Rimma Pivovarov; Herbert Chase; Vanja Dukic; Noémie Elhadad
Journal:  Stat Anal Data Min       Date:  2014-08-19       Impact factor: 1.051

2.  Flexible modeling of the hazard rate and treatment effects in long-term survival studies.

Authors:  Yolanda Hagar; James J Dignam; Vanja Dukic
Journal:  Stat Methods Med Res       Date:  2017-02-02       Impact factor: 3.021

3.  Bayesian Hierarchical Multiresolution Hazard Model for the Study of Time-Dependent Failure Patterns in Early Stage Breast Cancer.

Authors:  Vanja Dukić; James Dignam
Journal:  Bayesian Anal       Date:  2007-05-17       Impact factor: 3.728

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.